Physician profile
Adam E Strantz
NPI 1316220437
$2,930.04
in general payments reported to CMS, 2019-2025
22 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,229 · 2022: $618 · 2023: $490 · 2024: $151 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.45 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $742.30 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $369.45 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $273.14 | 2021-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $233.92 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $216.68 | 2021-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $197.45 | 2021-2023 | Rexulti |
| Alkermes, INC. | $178.69 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $136.33 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $121.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.84 | 2021-2022 | |
| Novo Nordisk INC | $61.71 | 2021 | |
| Vanda Pharmaceuticals INC. | $59.53 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $52.95 | 2021 | |
| Axsome Therapeutics, INC. | $46.32 | 2023-2025 | Sunosi |
| Alfasigma USA, INC. | $30.16 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.48 | 2021 | |
| Ironwood Pharmaceuticals, INC | $20.98 | 2021 | |
| Indivior INC. | $18.27 | 2023 | Perseris |
| Alexion Pharmaceuticals, INC. | $17.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.43 | 2023 | |
| Eisai INC. | $14.87 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Strantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.